The effect of cagrilintide and semaglutide combination treatment compared to a weight-loss inducing diet on energy metabolism in persons living with obesity: an open-label randomised study

Study Purpose: The purpose of this study is to provide insight into the effect of Cagrisema on energy metabolism compared with low energy diet alone.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if
you meet the following criteria:

Study Duration: ~82 weeks

Study Commitment: 1 screening visit (approximately 3-4 hours), up to 18 outpatient visit, three 3-night inpatient visits (total of 9 nights)

Age: 18-65 years old

Sex: Male & Female

Conditions/Eligibility: BMI ≥ 30.0 kg/m2, No Diabetes, no unusual eating habits or unwillingness to eat the food provided by the study, no treatment with Metformin or similar meds, no treatment for obesity or weight management within 90 days, must be able to have an MRI and DEXA scan, and other important criteria.

Study Procedures:
Alcohol and drug screening, tobacco use, pregnancy test, vital signs, weight / height, BMI, waist and hip measurements, EKG, Physical exam, blood and urine collection
DEXA and MRI
Medical and medication history
Activity Tracker
Diet and Physical Activity Counseling
Muscle biopsy (Optional)
Fat biopsy (Optional)
RMR (Resting Metabolic Rate)
Training in Trial Product, Injector Pen training
Completion of dosing diary
Home pregnancy tests (if applicable)
Home weights

Compensation: up to $16,125